DoctorDirectory.ai
Menu

Dr. Beverly Tchang, MD

Not yet claimed

Endocrinologist, Weight loss doctor, Internal medicine doctor · Physician (MD)

New York, NY · Telehealth in 0 states

Not yet claimed. This listing was researched from public sources and screened against our eligibility rules, but the provider has not yet claimed it, verified the details, or attested to guideline-based care. Are you Beverly Tchang? Claim this profile.

Associate Professor of Clinical Medicine at Weill Cornell Medical College and Associate Attending at NewYork-Presbyterian, triple board-certified in internal medicine, endocrinology and obesity medicine.

About Dr. Beverly Tchang, MD

Updated Sep 20, 2026 · next review Dec 19, 2026

Dr. Beverly Tchang is an endocrinologist and obesity medicine physician in New York City. She sees patients at NewYork-Presbyterian's Comprehensive Weight Control Center at 1305 York Avenue and at the Iris Cantor Women's Health Center, and she is an Associate Professor of Clinical Medicine at Weill Cornell Medical College.

She earned her medical degree from SUNY Downstate in 2013, completed residency at NewYork-Presbyterian/Weill Cornell, an endocrinology fellowship at NewYork-Presbyterian/Columbia, and an obesity medicine fellowship at NewYork-Presbyterian (2018-2019). She is board certified in internal medicine; endocrinology, diabetes and metabolism; and obesity medicine.

Her public work focuses on medicines used to treat obesity, such as GLP-1 drugs. She sits on The Obesity Society Governing Board (2025-2027), is president of the Tri-state Obesity Society, and co-authored a joint TOS/OMA/OAC expert guidance statement on obesity pharmacotherapy. She has been quoted in TODAY.com and Medscape about weight-loss medications and has recorded video commentary on how obesity guidelines are applied to individual patients.

She also has business and industry ties outside her clinical job: she runs Weightless Consulting LLC, advises the telehealth company Ro on obesity medicine, and has received payments from drug companies that are reported in the federal Open Payments database.

Board certifications
Board certified in internal medicine, obesity medicine, and endocrinology, diabetes and metabolism. weillcornell.org
Training and fellowships
Medical degree from SUNY Downstate (2013), residency at NewYork-Presbyterian/Weill Cornell, endocrinology fellowship at NewYork-Presbyterian/Columbia, and an obesity medicine fellowship at NewYork-Presbyterian in 2018-2019. doximity.com
Where she practices
Listed at NewYork-Presbyterian's Comprehensive Weight Control Center, 1305 York Avenue, for endocrinology, diabetes and metabolism and obesity medicine, and also at the Iris Cantor Women's Health Center. doctors.nyp.org
Academic appointment
Associate Professor of Clinical Medicine at Weill Cornell Medical College and president of the Tri-state Obesity Society. ihn.cuimc.columbia.edu
Obesity Society board
Serves as an at-large member of The Obesity Society Governing Board for 2025-2027. obesity.org
Guideline authorship
Co-authored the TOS/OMA/OAC expert guidance statement commentary on obesity pharmacotherapy published in Obesity, and was acknowledged for expert insight in the joint guidance on drug treatment of overweight and obesity in US adults. pubmed.ncbi.nlm.nih.gov
Research on weight medicines
Recent publications include a 2025 paper on semaglutide 2.4 mg and blood pressure and cholesterol medicines across five STEP trials, and papers on tirzepatide and on new mechanisms in obesity drug therapy. vivo.weill.cornell.edu
National committee work
Has served on national committees at AACE, The Obesity Society, the American Society of Nutrition and ASPEN, and teaches in the ObesityWeek Mastery Course. obesityweek.org
Advice in the media
In a TODAY.com guide to Wegovy and Zepbound, she advised patients to start by talking with their own doctor, often primary care, about whether they are a candidate, side effects, and long-term considerations. today.com
Views on guidelines and food
Has given public commentary comparing Canadian obesity guidelines with the Lancet Commission, on applying guidelines to individual patients, and on the need for more research into why ultraprocessed foods are linked to eating more. medscape.com

Worth knowing

  • Federal Open Payments records show $119,004.15 in industry payments across 103 records from 2021 to 2025. The largest payers were Novo Nordisk ($71,659.69), Boehringer Ingelheim ($20,226.36), Eli Lilly ($16,273.72), Amgen ($4,470) and F. Hoffmann-La Roche ($2,700). Several of these companies make obesity and diabetes medicines. Industry payments to physicians are common and legal, and are reported publicly. openpaymentsdata.cms.gov
  • A publisher author page accompanying her commentary writing discloses $5,525 in consulting fees from Novo Nordisk in 2022 and a disclosed relationship with Gelesis. blogs.the-hospitalist.org
  • In addition to her hospital role, she serves as an obesity medicine advisor to the telehealth company Ro and formed Weightless Consulting LLC in 2020 to work with science and technology companies. ro.co

Industry payments (CMS Open Payments)

Open the CMS record

Federal law requires drug and device companies to report what they pay clinicians: meals, travel, speaking, consulting, and research. Payments are common and legal; the point is that you can see them.

2021 to 2025

$119,004

103 payments

2021$3,133
2022$6,695
2023$12,390
2024$26,067
2025$70,720

Top payers

  • Novo Nordisk Inc$71,660
  • Boehringer Ingelheim Pharmaceuticals, Inc.$20,226
  • Eli Lilly and Company$16,274
  • Amgen Inc.$4,470
  • F. Hoffmann-La Roche AG$2,700

Payment types

  • Consulting Fee$98,128
  • Travel and Lodging$17,000
  • Food and Beverage$3,877

A word of caution about these numbers

A payment does not mean your doctor is compromised or acting unethically. Most of these entries are drug samples left for patients, or lunch brought in for the office staff, and the amounts are usually small. Research funding and speaking at medical meetings are also normal parts of a clinical career.

As a rough guide, a total under $15,000 a year is usually not a concern. Much larger sums, especially from one company whose product your doctor recommends to you, are worth asking about. You are allowed to ask.

Sources: weillcornell.org · doctors.nyp.org · doctors.nyp.org · vivo.weill.cornell.edu · linkedin.com · doximity.com · healthgrades.com · ihn.cuimc.columbia.edu. Something wrong or out of date? Tell us and we will correct it.

Summary prepared with AI assistance from the public sources linked above, reviewed every three months. It is not a review, a rating, or an endorsement.

Practice location

Something wrong with this profile? ·